Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.

Autor:	Kobe EA; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA., Thakkar A; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA., Matai S; Raleigh Charter High School, 1307 Glenwood Ave, Raleigh, NC 27605, USA., Akkaya E; Duke University School of Medicine, 8 Searle Center Dr, Durham, NC 27710, USA.; Duke Molecular Physiology Institute, 300 N Duke St, Durham, NC 27701, USA., Pagidipati NJ; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA.; Duke University School of Medicine, 8 Searle Center Dr, Durham, NC 27710, USA.; Duke Clinical Research Institute, 300 W Morgan St, Durham, NC 27701, USA., McGarrah RW; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA.; Duke University School of Medicine, 8 Searle Center Dr, Durham, NC 27710, USA.; Duke Molecular Physiology Institute, 300 N Duke St, Durham, NC 27701, USA., Bloomfield GS; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA.; Duke Clinical Research Institute, 300 W Morgan St, Durham, NC 27701, USA.; Duke Global Health Institute, 310 Trent Dr, Durham, NC 27710, USA., Shah NP; Duke University Hospitals, 2301 Erwin Road, Suite 7400, Cubicle 13, Durham, NC 27710, USA.; Duke University School of Medicine, 8 Searle Center Dr, Durham, NC 27710, USA.; Duke Clinical Research Institute, 300 W Morgan St, Durham, NC 27701, USA.
Jazyk:	angličtina
Zdroj:	American journal of preventive cardiology [Am J Prev Cardiol] 2024 Oct 28; Vol. 20, pp. 100888. Date of Electronic Publication: 2024 Oct 28 (Print Publication: 2024).
DOI:	10.1016/j.ajpc.2024.100888
Abstrakt:	Effective antiretroviral therapy (ART) is now nearly ubiquitous. However, the survival benefits conferred with ART contribute to an aging human immunodeficiency virus (HIV) population and increased risk of chronic diseases, like atherosclerotic cardiovascular disease (ASCVD). Furthermore, HIV is a known risk enhancer of ASCVD and acknowledged as such in the current 2018 AHA/ACC Blood Cholesterol guidelines [1]. This makes cardiovascular risk factor identification and modification among people living with HIV (PLWH) of increasing importance to prevent cardiovascular events. In this review, we aim to summarize the epidemiology and pathogenesis of how HIV is linked to atherogenesis and to discuss cardiometabolic risk factor modification specific to PLWH, covering obesity, hypertension, insulin resistance, metabolic dysfunction-associated steatotic liver disease, and dyslipidemia. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Neha J. Pagidipati reports financial support was provided by Amgen. Neha J. Pagidipati reports financial support was provided by AstraZeneca. Neha J. Pagidipati reports financial support was provided by Baseline Study LLC. Neha J. Pagidipati reports financial support was provided by Boehringer Ingelheim. Neha J. Pagidipati reports financial support was provided by Duke University Duke Clinical Research Institute. Neha J. Pagidipati reports financial support was provided by Eggland's Best. Neha J. Pagidipati reports financial support was provided by Eli Lilly and Company. Neha J. Pagidipati reports financial support was provided by Novartis. Neha J. Pagidipati reports financial support was provided by Novo Nordisk Pharmaceuticals. Neha J. Pagidipati reports financial support was provided by Sanofi-S.A. Neha J. Pagidipati reports financial support was provided by Verily Sciences Research Company. Nishant P. Shah reports financial support was provided by Amgen Inc. Nishant P. Shah reports financial support was provided by Janssen. Nishant P. Shah reports financial support was provided by National Institutes of Health. Nishant P. Shah reports a relationship with Esperion Therapeutics Inc that includes: consulting or advisory. Nishant P. Shah reports a relationship with Amgen Inc that includes: consulting or advisory. Nishant P. Shah reports a relationship with Novartis that includes: consulting or advisory. Neha J. Pagidipati reports a relationship with AstraZeneca that includes: consulting or advisory. Neha J. Pagidipati reports a relationship with Boehringer Ingelheim that includes: consulting or advisory. Neha J. Pagidipati reports a relationship with Esperion Therapeutics Inc that includes: consulting or advisory. Neha J. Pagidipati reports a relationship with Eli Lilly and Company that includes: consulting or advisory. Neha J. Pagidipati reports a relationship with Novo Nordisk Pharmaceuticals SA that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu